logo-loader
viewAIM ImmunoTech Inc.

Hemispherx Biopharma doses first patient with Ampligen in Phase 1 advanced breast cancer study

Hemispherx Biopharma Inc (NYSEAMERICAN:HEB) CEO Tom Equels tells Proactive Investors the company is excited to begin its Phase 1 studies using Ampligen as a combination therapy with Merck's Keytruda cancer drug at the Roswell Park Comprehensive Cancer Center in New York.

The study will establish the safety of the therapies to treat advanced breast cancer. Equels anticipates safety and efficacy indicators six to nine months after full enrollment of the study.

Quick facts: AIM ImmunoTech Inc.

Price: 0.4001 USD

NYSE:AIM
Market: NYSE
Market Cap: $3.31 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of AIM ImmunoTech Inc. named herein, including the promotion by the Company of AIM ImmunoTech Inc. in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Hemispherx Biopharma releases 'well tolerated' data for...

Hemispherx Biopharma Inc (NYSEAMERICAN:HEB) CEO Thomas Equels tells Protactive that a final report on its phase 1 trial supporting the safety of using its flagship drug Ampligen as a combination therapy to treat recurrent ovarian cancer found that it was “well tolerated." Equels explains the...

on 08/19/2019

2 min read